{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-330644","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2026-08-03T20:24:23+00:00","discovered_at":"2026-08-03T20:25:00.381967+00:00","generated_at":"2026-08-03T20:25:06.812680+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CRISPR Q2 CASGEVY revenue $76M (+151% YoY); FDA expands approval to children 2+","bullets":["CASGEVY Q2 revenue $76M, up 78% QoQ and 151% YoY; FDA approved for children 2+ with SCD/TDT, adding ~5,500 eligible patients.","Initiated Phase 1 trials for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency) using in vivo LNP delivery.","Cash $2.36B at June 30, 2026, up from $1.98B at Dec 31, 2025, boosted by $585M convertible note issuance.","Net loss narrowed to $91.2M from $208.5M in Q2 2025, driven by lower acquired IPR&D and higher CASGEVY revenue.","Phase 1b update for CTX310 (ANGPTL3) expected at ESC Congress Aug 28; Phase 2 for CTX611 (FXI siRNA) ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-330644","json":"https://secwatch.observer/filing/0001193125-26-330644.json","markdown":"https://secwatch.observer/filing/0001193125-26-330644.md","text":"https://secwatch.observer/filing/0001193125-26-330644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526330644/0001193125-26-330644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526330644/crsp-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T20:25:06.812680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}